Efficacy and safety of rituximab treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitides: Results from a German registry (GRAID)

Petra Roll; Eva Ostermeier; Marion Haubitz; Svjetlana Lovric; Leonore Unger; Julia Holle; Ina Kötter; Jörg C. Henes; Raoul Bergner; Andrea Rubbert-Roth; Christof Specker; Hendrik Schulze-Koops; Ulf Müller-Ladner; Martin Fleck; Gerd Rüdiger Burmester; Falk Hiepe; Stefan Heitmann; Martin Aringer; Rebecca Fischer-Betz; Thomas Dörner; Hans Peter Tony

doi:10.3899/jrheum.120482

Efficacy and safety of rituximab treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitides: Results from a German registry (GRAID)

Petra Roll^*, Eva Ostermeier, Marion Haubitz, Svjetlana Lovric, Leonore Unger, Julia Holle, Ina Kötter, Jörg C. Henes, Raoul Bergner, Andrea Rubbert-Roth, Christof Specker, Hendrik Schulze-Koops, Ulf Müller-Ladner, Martin Fleck, Gerd Rüdiger Burmester, Falk Hiepe, Stefan Heitmann, Martin Aringer, Rebecca Fischer-Betz, Thomas DörnerHans Peter Tony

^*Corresponding author for this work

Department of Rheumatology and Clinical Immunology

34 Citations (Scopus)

Abstract

Objective. Rituximab (RTX) therapy is a treatment option in patients with refractory antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). We investigated the tolerability and clinical efficacy of RTX in a cohort of patients with refractory AAV. Methods. Clinical and safety data of patients with AAV treated with RTX were retrospectively assessed from the data of a German national registry. Results. In total, 58 patients were included in this analysis (50/58 with granulomatosis with poly-angiitis; 8/58 with microscopic polyangiitis who received at least 1 cycle, 17 patients who received 2 cycles, and 3 patients who received 3 cycles of RTX). Response was classified as complete and partial in 22 (40%) and in 29 cases (52.7%), respectively. Four patients (7.3%) were classified as nonresponders. Conclusion. RTX was well tolerated with good clinical efficacy in patients with refractory AAV. The Journal of Rheumatology

Original language	English
Journal	Journal of Rheumatology
Volume	39
Issue number	11
Pages (from-to)	2153-2156
Number of pages	4
ISSN	0315-162X
DOIs	https://doi.org/10.3899/jrheum.120482
Publication status	Published - 01.11.2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.3899/jrheum.120482

Cite this

Roll, P., Ostermeier, E., Haubitz, M., Lovric, S., Unger, L., Holle, J., Kötter, I., Henes, J. C., Bergner, R., Rubbert-Roth, A., Specker, C., Schulze-Koops, H., Müller-Ladner, U., Fleck, M., Burmester, G. R., Hiepe, F., Heitmann, S., Aringer, M., Fischer-Betz, R., ... Tony, H. P. (2012). Efficacy and safety of rituximab treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitides: Results from a German registry (GRAID). Journal of Rheumatology, 39(11), 2153-2156. https://doi.org/10.3899/jrheum.120482

@article{c11b6135ebbe48bfb58a5495d2a52433,

title = "Efficacy and safety of rituximab treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitides: Results from a German registry (GRAID)",

abstract = "Objective. Rituximab (RTX) therapy is a treatment option in patients with refractory antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). We investigated the tolerability and clinical efficacy of RTX in a cohort of patients with refractory AAV. Methods. Clinical and safety data of patients with AAV treated with RTX were retrospectively assessed from the data of a German national registry. Results. In total, 58 patients were included in this analysis (50/58 with granulomatosis with poly-angiitis; 8/58 with microscopic polyangiitis who received at least 1 cycle, 17 patients who received 2 cycles, and 3 patients who received 3 cycles of RTX). Response was classified as complete and partial in 22 (40\%) and in 29 cases (52.7\%), respectively. Four patients (7.3\%) were classified as nonresponders. Conclusion. RTX was well tolerated with good clinical efficacy in patients with refractory AAV. The Journal of Rheumatology",

author = "Petra Roll and Eva Ostermeier and Marion Haubitz and Svjetlana Lovric and Leonore Unger and Julia Holle and Ina K{\"o}tter and Henes, \{J{\"o}rg C.\} and Raoul Bergner and Andrea Rubbert-Roth and Christof Specker and Hendrik Schulze-Koops and Ulf M{\"u}ller-Ladner and Martin Fleck and Burmester, \{Gerd R{\"u}diger\} and Falk Hiepe and Stefan Heitmann and Martin Aringer and Rebecca Fischer-Betz and Thomas D{\"o}rner and Tony, \{Hans Peter\}",

year = "2012",

month = nov,

day = "1",

doi = "10.3899/jrheum.120482",

language = "English",

volume = "39",

pages = "2153--2156",

journal = "Journal of Rheumatology",

issn = "0315-162X",

publisher = "Journal of Rheumatology",

number = "11",

}

Roll, P, Ostermeier, E, Haubitz, M, Lovric, S, Unger, L, Holle, J, Kötter, I, Henes, JC, Bergner, R, Rubbert-Roth, A, Specker, C, Schulze-Koops, H, Müller-Ladner, U, Fleck, M, Burmester, GR, Hiepe, F, Heitmann, S, Aringer, M, Fischer-Betz, R, Dörner, T & Tony, HP 2012, 'Efficacy and safety of rituximab treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitides: Results from a German registry (GRAID)', Journal of Rheumatology, vol. 39, no. 11, pp. 2153-2156. https://doi.org/10.3899/jrheum.120482

Efficacy and safety of rituximab treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitides: Results from a German registry (GRAID). / Roll, Petra; Ostermeier, Eva; Haubitz, Marion et al.
In: Journal of Rheumatology, Vol. 39, No. 11, 01.11.2012, p. 2153-2156.

Research output: Journal Articles › Journal articles › Research › peer-review

TY - JOUR

T1 - Efficacy and safety of rituximab treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitides: Results from a German registry (GRAID)

AU - Roll, Petra

AU - Ostermeier, Eva

AU - Haubitz, Marion

AU - Lovric, Svjetlana

AU - Unger, Leonore

AU - Holle, Julia

AU - Kötter, Ina

AU - Henes, Jörg C.

AU - Bergner, Raoul

AU - Rubbert-Roth, Andrea

AU - Specker, Christof

AU - Schulze-Koops, Hendrik

AU - Müller-Ladner, Ulf

AU - Fleck, Martin

AU - Burmester, Gerd Rüdiger

AU - Hiepe, Falk

AU - Heitmann, Stefan

AU - Aringer, Martin

AU - Fischer-Betz, Rebecca

AU - Dörner, Thomas

AU - Tony, Hans Peter

PY - 2012/11/1

Y1 - 2012/11/1

N2 - Objective. Rituximab (RTX) therapy is a treatment option in patients with refractory antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). We investigated the tolerability and clinical efficacy of RTX in a cohort of patients with refractory AAV. Methods. Clinical and safety data of patients with AAV treated with RTX were retrospectively assessed from the data of a German national registry. Results. In total, 58 patients were included in this analysis (50/58 with granulomatosis with poly-angiitis; 8/58 with microscopic polyangiitis who received at least 1 cycle, 17 patients who received 2 cycles, and 3 patients who received 3 cycles of RTX). Response was classified as complete and partial in 22 (40%) and in 29 cases (52.7%), respectively. Four patients (7.3%) were classified as nonresponders. Conclusion. RTX was well tolerated with good clinical efficacy in patients with refractory AAV. The Journal of Rheumatology

AB - Objective. Rituximab (RTX) therapy is a treatment option in patients with refractory antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). We investigated the tolerability and clinical efficacy of RTX in a cohort of patients with refractory AAV. Methods. Clinical and safety data of patients with AAV treated with RTX were retrospectively assessed from the data of a German national registry. Results. In total, 58 patients were included in this analysis (50/58 with granulomatosis with poly-angiitis; 8/58 with microscopic polyangiitis who received at least 1 cycle, 17 patients who received 2 cycles, and 3 patients who received 3 cycles of RTX). Response was classified as complete and partial in 22 (40%) and in 29 cases (52.7%), respectively. Four patients (7.3%) were classified as nonresponders. Conclusion. RTX was well tolerated with good clinical efficacy in patients with refractory AAV. The Journal of Rheumatology

UR - https://www.scopus.com/pages/publications/84868382114

U2 - 10.3899/jrheum.120482

DO - 10.3899/jrheum.120482

M3 - Journal articles

C2 - 22984269

AN - SCOPUS:84868382114

SN - 0315-162X

VL - 39

SP - 2153

EP - 2156

JO - Journal of Rheumatology

JF - Journal of Rheumatology

IS - 11

ER -

Efficacy and safety of rituximab treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitides: Results from a German registry (GRAID)

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this